How does AP8's PB Ratio compare to its peers?

AP8 is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (0.6x).

How does AP8's PB Ratio compare vs other companies in the DE Biotechs Industry?

AP8 is good value based on its Price-To-Book Ratio (0.2x) compared to the European Biotechs industry average (2.4x).

What is AP8's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate AP8's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of AP8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate AP8's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Aptevo Therapeutics (DB:AP8) - Stock Price, News & Analysis

AP8 Stock Overview

A clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. More details

AP8 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap (€1M)

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

+ 1 more risk

Aptevo Therapeutics Inc. Competitors

bioXXmed

XTRA:T5O

€1.4m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€22.6m

4SC

DB:VSC

€49.1m

Price History & Performance

Summary of all time highs, changes and price drops for Aptevo Therapeutics
Historical stock prices
Current Share Price	US$4.95
52 Week High	US$70.14
52 Week Low	US$0.019
Beta	5.12
11 Month Change	0%
3 Month Change	-9.07%
1 Year Change	-92.17%
33 Year Change	-99.47%
5 Year Change	-98.77%
Change since IPO	-99.72%

Recent updates

Shareholder Returns

	AP8	DE Biotechs	DE Market
7D	0%	-0.7%	-0.02%
1Y	-92.2%	-17.2%	8.2%

Return vs Industry: AP8 underperformed the German Biotechs industry which returned -23.7% over the past year.

Return vs Market: AP8 underperformed the German Market which returned 3.2% over the past year.

Price Volatility

Is AP8's price volatile compared to industry and market?
AP8 volatility
AP8 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: AP8's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine AP8's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	40	Marvin White	www.aptevotherapeutics.com

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company’s lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia.

Aptevo Therapeutics Inc. Fundamentals Summary

How do Aptevo Therapeutics's earnings and revenue compare to its market cap?
AP8 fundamental statistics
Market cap	€1.06m
Earnings (TTM)	-€25.18m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is AP8 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AP8 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$17.11m
Gross Profit	-US$17.11m
Other Expenses	US$10.20m
Earnings	-US$27.31m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-17.00
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did AP8 perform over the long term?

See historical performance and comparison

AP8 Stock Overview

Risk Analysis

Aptevo Therapeutics Inc. Competitors

XTRA:T5O

€1.4m

XTRA:CNW

€6.5m

XTRA:MDG1

€22.6m

DB:VSC

€49.1m

Price History & Performance

Recent News & Updates

Aptevo Therapeutics Expands on the Potential of Mipletamig

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.999493 million.

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Recent updates

Aptevo Therapeutics Expands on the Potential of Mipletamig

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.999493 million.

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Aptevo Therapeutics Inc. Announces That Phase 1B/2 "Rainier" Frontline Acute Myeloid Leukemia (Aml) Trial Initiated

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5550(a)(2)

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Share price stability

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings released: EPS: US$1.38 (vs US$6.27 loss in FY 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$5.55 (vs US$1.78 loss in 2Q 2021)

Forecast to breakeven in 2022

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

First quarter 2022 earnings released: US$1.60 loss per share (vs US$1.74 loss in 1Q 2021)

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Shareholder Returns

Price Volatility

About the Company

Aptevo Therapeutics Inc. Fundamentals Summary

0.0x

0.0x

Earnings & Revenue